Search Results
Your search for Matthew Stenger ,Matthew Stenger matches 7472 pages
Showing 101 - 150Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer
In an Austrian study reported in the Journal of Clinical Oncology, Brunner et al identified the incidence of medication-related osteonecrosis of the jaw over 20 years of follow-up in patients with breast cancer who had bone metastases and were receiving antiresorptive medication. Study Details and...
Ponatinib With Chemotherapy for Newly Diagnosed Philadelphia Chromosome–Positive ALL
On March 19, 2024, ponatinib (Iclusig) was granted accelerated approval for use with chemotherapy in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL).1 Ponatinib is a multitargeted kinase inhibitor. Supporting Efficacy Data and How It Is Used Approval ...
Inotuzumab Ozogamicin for Pediatric Acute Lymphoblastic Leukemia
On March 6, 2024, the anti-CD22 monoclonal antibody inotuzumab ozogamicin (Besponsa), which is bound to a toxic natural calicheamicin, was approved for pediatric patients aged 1 year or older with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia.1 Supporting...
CAR T-Cell Therapy in Refractory Follicular Lymphoma
On May 15, 2024, lisocabtagene maraleucel (Breyanzi) was granted accelerated approval for adults with relapsed or refractory follicular lymphoma with two or more prior lines of systemic therapy.1 The agent is a CD19-directed genetically modified autologous T-cell immunotherapy. Supporting Efficacy...
Hypofractionated vs Conventionally Fractionated Radiation After Implant-Based Breast Reconstruction
In a trial reported in JAMA Oncology, Julia S. Wong, MD, and colleagues found that hypofractionated postmastectomy radiation therapy did not improve outcomes in the physical well-being domain of the Functional Assessment of Cancer Therapy–Breast (FACT-B) assessment vs conventionally fractionated...
Inoperable Stage III NSCLC: Adaptive Radiotherapy Based on FDG-PET Tumor Residual Uptake
In a French phase II study (RTEP7–IFCT-1402) reported in The Lancet Oncology, Vera et al found that adaptive radiotherapy based on fluorine F-18–labeled fluorodeoxyglucose (FDG)–positron-emission tomography (PET) residual uptake appeared to improve local disease control compared with standard...
Menin Inhibitor in KMT2A-Rearranged Relapsed or Refractory Acute Leukemia
In a phase I/II study (AUGMENT-101) reported in the Journal of Clinical Oncology, Issa et al found that revumenib, an oral small-molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, was active in patients with KMT2A-rearranged (KMT2A) relapsed or refractory acute...
Advanced Biliary Tract Cancers: Bevacizumab/Erlotinib Maintenance vs Active Surveillance
In an Indian phase II trial (BEER BTC) reported in the Journal of Clinical Oncology, Ramaswamy et al found that maintenance therapy with bevacizumab/erlotinib improved progression-free survival vs active surveillance in patients with advanced biliary tract cancers who had at least stable disease...
First-Line Nivolumab/Relatlimab vs Nivolumab/Ipilimumab in Advanced Melanoma
In an analysis reported in the Journal of Clinical Oncology, Georgina V. Long, PhD, MBBS, and colleagues performed an indirect comparison of outcomes with first-line nivolumab/relatlimab vs nivolumab/ipilimumab for advanced melanoma using patient-level data from trials supporting approval of the...
Metastatic Pancreatic Adenocarcinoma: Addition of Devimistat to mFFX
As reported in the Journal of Clinical Oncology, Philip et al found that the phase III AVENGER 500 study showed no overall survival benefit with devimistat plus modified fluorouracil, oxaliplatin, irinotecan, and leucovorin (mFFX) vs FFX in patients with metastatic pancreatic adenocarcinoma. As...
Breast-Conserving Surgery With or Without Postoperative Radiotherapy in Early-Stage Breast Cancer: 30-Year Update
As reported in The Lancet Oncology by Williams et al, long-term follow-up of the phase III Scottish Breast Conservation Trial indicated that postoperative radiotherapy was associated with a significantly reduced risk of ipsilateral recurrence vs no radiotherapy in patients undergoing...
Long-Term Look at Selpercatinib in RET-Activated Thyroid Cancer
In an analysis of the phase I/II LIBRETTO-001 trial reported in the Journal of Clinical Oncology, Lori J. Wirth, MD, and colleagues provided the long-term outcomes of selpercatinib treatment among patients with RET-activated thyroid cancer. Study Details The analysis included patients with...
Causal Attribution of HPV Genotypes to Invasive Cervical Cancer
In a systemic analysis of global literature reported in The Lancet, Wei et al estimated the proportion of invasive cervical cancer cases caused by specific human papillomavirus (HPV) genotypes. Study Details A literature search through February 2024 was performed to identify studies reporting HPV...
Recurrent or Advanced Endometrial Cancer: Atezolizumab Plus Chemotherapy
As reported in The Lancet Oncology by Nicoletta Colombo, MD, and colleagues, the phase III AtTEnd trial showed improved progression-free survival with the addition of atezolizumab to chemotherapy in patients with recurrent or advanced endometrial cancer, particularly among those with mismatch...
Corticosteroids for Immune-Related Adverse Events and Clinical Outcomes With ICIs for Solid Tumors
In an analysis reported in the Journal of Clinical Oncology, Verheijden et al found that higher peak corticosteroid doses for patients with immune-related adverse events were associated with poorer outcomes in patients receiving immune checkpoint inhibitors (ICIs) for solid tumors. Study Details...
Completion Axillary Lymph Node Dissection to Select Adjuvant Treatment in Breast Cancer and Associated Impairment of Arm Function
In an analysis involving the phase III SENOMAC trial reported in The Lancet Oncology, de Boniface et al found that the use of completion axillary lymph node dissection (cALND) to identify pN2-3 status (at least four nodal metastases) in patients with breast cancer, and thus qualification for...
T-DXd in HER2-Positive Advanced Colorectal Cancer
As reported in The Lancet Oncology by Kanwal Raghav, MD, and colleagues, the phase II DESTINY-CRC02 trial has identified the preferred dosage of single-agent fam-trastuzumab deruxtecan-nxki (T-DXd) in patients with HER2-positive advanced colorectal cancer. Study Details In the international study, ...
Resected Melanoma: Subsequent Systemic Therapy After Recurrence on Adjuvant Nivolumab
In an analysis from the phase III CheckMate 238 trial reported in the Journal of Clinical Oncology, Jeffrey Weber, MD, PhD, and colleagues found that progression-free and overall survival were improved with subsequent systemic therapy following late vs early recurrence with adjuvant nivolumab in...
Advanced GIST: Long-Term Outcomes With Discontinuation vs Continuation of Imatinib
In a long-term follow-up of a French phase III trial (BFR14) reported in The Lancet Oncology, Jean-Yves Blay, MD, and colleagues found that discontinuation of imatinib in patients with advanced gastrointestinal stromal tumors (GIST) with at least stable disease was associated with markedly poorer...
Association of Regular Aspirin Use With Colorectal Cancer Risk According to Lifestyle Factors
In a study reported in JAMA Oncology, Sikavi et al found that regular aspirin use was associated with a reduced risk of colorectal cancer overall and among individuals with less healthy vs more healthy lifestyles. Study Details The prospective cohort study focused on data from 107,655 participants...
Cannabis Use and Risk of Head and Neck Cancer
In a study reported in JAMA Otolaryngology–Head & Neck Surgery, Gallagher et al found that individuals with cannabis-related disorder were at an increased risk of head and neck cancer vs those without cannabis-related disorder. Cannabis-related disorders are defined by the excessive use of...
Visceral Pleural Invasion and Recurrence Risk in Patients Undergoing Surgery for NSCLC
In an analysis from the CALGB 140503 trial reported in JAMA Oncology, Nasser Altorki, MD, and colleagues found that pathologically identified visceral pleural invasion was associated with poorer outcomes in patients undergoing surgery for non–small cell lung cancer (NSCLC). Study Details The trial ...
Merkel Cell Carcinoma: Association of ctDNA With Recurrence Risk
In a study reported in the Journal of Clinical Oncology, Akaike et al found that detection of circulating tumor DNA (ctDNA) was associated with an increased risk of recurrence in patients with Merkel cell carcinoma. Study Details In the study, a tumor-informed ctDNA assay was used in 319 patients...
EGFR- and ALK-Altered NSCLC: TKIs With Stereotactic Radiosurgery for Brain Metastases
In a retrospective study (TURBO-NSCLC) reported in the Journal of Clinical Oncology, Pike et al found that the addition of upfront stereotactic radiosurgery (SRS) to central nervous system (CNS)-penetrant tyrosine kinase inhibitor (TKI) treatment prolonged time to CNS progression vs TKI treatment...
Lorlatinib vs Crizotinib in Advanced ALK-Positive NSCLC: 5-Year Outcomes From Phase III CROWN Trial
In an article in the Journal of Clinical Oncology, corresponding author Benjamin J. Solomon, MBBS, BS, PhD, of Peter MacCallum Cancer Centre, Melbourne, and colleagues provided a long-term analysis of 5-year outcomes from the phase III CROWN trial.1 Median progression-free survival had not been...
Cancer of Unknown Primary: Molecularly Guided Therapy After Disease Control on Platinum-Based Chemotherapy
In the phase II CUPISCO trial reported in The Lancet, Krämer et al found that molecularly guided therapy in patients with unfavorable nonsquamous cancer of unknown primary who had disease control on first-line platinum-based therapy resulted in better progression-free survival vs patients who...
Births and Adverse Obstetric Outcomes Among Female Survivors of Adolescent and Young Adult Cancers
In a population-based retrospective cohort study (Teenage and Young Adult Cancer Survivor Study; TYACSS) reported in The Lancet Oncology, Sunguc et al identified risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancers in England and Wales. Study Details The...
EGFR-Mutated NSCLC: Tepotinib/Osimertinib in Patients With MET Amplification
In the phase II INSIGHT 2 trial reported in The Lancet Oncology, Yi-Long Wu, MD, and colleagues found that the combination of tepotinib plus osimertinib showed clinically meaningful activity in patients with advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) with MET...
Sacituzumab Govitecan in Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Alessandro D. Santin, MD, and colleagues, findings in the endometrial cancer cohort of the phase II multicohort TROPiCS-03 trial indicated activity of the Trop-2–directed antibody-drug conjugate sacituzumab govitecan-hziy in pretreated patients...
Ponatinib and Blinatumomab in Newly Diagnosed Ph-Positive ALL
In an updated analysis of a single-center phase II trial reported in the Journal of Clinical Oncology, Hagop Kantarjian, MD, and colleagues found that the simultaneous combination of ponatinib and blinatumomab continued to be associated with good outcomes in newly diagnosed patients with...
Estrogen Plus Progestin and Risk of Colorectal Cancer
As reported in the Journal of Clinical Oncology by Rowan T. Chlebowski, MD, PhD, and colleagues, long-term follow-up of the Women’s Health Initiative trial showed no benefit of treatment with estrogen plus progestin in reducing the risk of colorectal cancer in postmenopausal women. Study Details...
Recurrent/Metastatic HNSCC: Pembrolizumab Plus Carboplatin and Paclitaxel
As reported in the Journal of Clinical Oncology by Marcin Dzienis, MD, and colleagues, the phase IV KEYNOTE-B10 trial of pembrolizumab plus carboplatin and paclitaxel in the first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) showed that the regimen produced...
Early-Stage Breast Cancer: MammaPrint Prediction of Extended Letrozole Benefit
In an analysis from the NRG Oncology/NSABP B-42 trial reported in the Journal of Clinical Oncology, Priya Rastogi, MD, and colleagues found that the 70-gene MammaPrint assay findings did not predict the distant recurrence benefit of extended letrozole therapy vs placebo in patients with...
Advanced NSCLC: Association of Intratumoral Escherichia With Overall Survival
In a study reported in the Journal of Clinical Oncology, Arielle Elkrief, MD, and colleagues found that detection of intratumoral Escherichia was associated with improved overall survival in patients with advanced non–small cell lung cancer (NSCLC) receiving single-agent immune checkpoint inhibitor ...
Effect of Posttransplantation Cyclophosphamide-Based GVHD Prophylaxis on Patients With Hematologic Malignancies
In an analysis reported in the Journal of Clinical Oncology, Shaffer et al found that use of post–allogeneic hematopoietic cell transplantation (HCT) cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis resulted in comparable overall survival and GVHD-free, relapse-free survival...
MRD-Negative ALL: Addition of Blinatumomab to Consolidation Chemotherapy
In the phase III ECOG-ACRIN E1910 trial reported in The New England Journal of Medicine, Mark R. Litzow, MD, and colleagues found that the addition of blinatumomab to consolidation chemotherapy improved overall survival among adult patients with BCR-ABL fusion–negative B-cell precursor acute...
Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer
In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Study Details In the ...
Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors: Long-Term Outcomes
In a long-term analysis reported in the Journal of Clinical Oncology, Gleeson et al found that initial salvage treatment for germ cell tumors with paclitaxel, ifosfamide, and cisplatin (TIP) was associated with positive long-term outcomes in both favorable- and unfavorable-risk disease. Study...
Addition of Ibrutinib to Immunochemotherapy and ASCT Improves Survival in Mantle Cell Lymphoma
As reported in The Lancet by Martin Dreyling, MD, PhD, of Ludwig Maximilian University Hospital Munich, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell...
Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration...
RSClin Tool and Risk for Late Distant Recurrence in Breast Cancer
In a study reported in NEJM Evidence, Joseph A. Sparano, MD, and colleagues found that a risk score integrating the 21-gene recurrence score (RS) with clinicopathologic factors—the RSClin tool—performed well in predicting risk of late distant recurrence in patients with breast cancer. Study...
Neoadjuvant Camrelizumab Plus Apatinib in Locally Advanced Colorectal Cancer
In a Chinese phase II study (NEOCAP) reported in The Lancet Oncology, Yu et al found that neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch repair–deficient colorectal cancer. Study ...
Pancreatic Cancer: Celiac Plexus Radiosurgery for Retroperitoneal Pain Syndrome
In a phase II study reported in The Lancet Oncology, Lawrence et al found that celiac plexus radiosurgery showed promise in the alleviation of retroperitoneal pain syndrome in patients with pancreatic cancer or other tumors involving the celiac axis. Study Details Between January 2018 and December...
Immunotherapy in Unresectable HCC With Child-Pugh Class B Dysfunction
In a retrospective study reported in JAMA Oncology, Fulgenzi et al found evidence that immune checkpoint inhibitor (ICI)-based treatment may improve survival vs best supportive care as first-line therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh class B (CP-B) liver...
Tailored Dose-Dense Adjuvant Chemotherapy in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Matikas et al, the prespecified end-of-study analysis of the European phase III PANTHER trial showed significant improvements in outcomes with tailored dose-dense vs standard adjuvant chemotherapy in patients with high-risk early breast cancer. As...
pMMR/MSS Locally Advanced Rectal Cancer: Immunotherapy-Based Total Neoadjuvant Therapy
In a Chinese phase II trial (TORCH) reported in the Journal of Clinical Oncology, Xia et al found that integration of the PD-1 inhibitor toripalimab into total neoadjuvant therapy was associated with good outcomes in patients with mismatch repair–proficient or microsatellite-stable (pMMR/MSS)...
Early Breast Cancer: Genetic Testing and Communication of Results With Family After Diagnosis
In a U.S. study reported in the Journal of Clinical Oncology, Steven J. Katz, MD, MPH, and colleagues found that many women with early breast cancer and indications for genetic testing do not undergo said testing. Study Details The study involved data from 1,412 women aged 20 to 79 years...
Response-Adapted Radiation Therapy for Orbital Indolent B-Cell Lymphoma
In a single-institution phase II trial reported in JAMA Oncology, Pinnix et al found that response-adapted radiation therapy featuring ultra–low-dose radiation therapy was a successful strategy in patients with indolent B-cell lymphoma of the ocular adnexa. As stated by the investigators:...
EGFR-HER3 Bispecific Antibody-Drug Conjugate in Locally Advanced or Metastatic Solid Tumors
In a Chinese phase I trial reported in The Lancet Oncology, Ma et al found that BL-B01D1—a first-in-class EGFR-HER3 bispecific antibody-drug conjugate—was active in previously treated patients with locally advanced or metastatic solid tumors. Study Details In the multicenter trial, 195 patients...
LBCL: CD22-Directed CAR T-Cell Therapy After Disease Progression on CD19-Directed CAR T-Cell Therapy
In a single-center phase I trial reported in The Lancet, Frank et al found that CD22-directed chimeric antigen receptor (CAR) T-cell therapy (CAR22) showed activity in patients with large B-cell lymphoma (LBCL) whose disease progressed on CD19-directed CAR T-cell therapy (CAR19). CD22 is a nearly...
